Boston Scientific Co. (NYSE:BSX) Shares Sold by Legal & General Group Plc

Legal & General Group Plc reduced its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 20.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,738,806 shares of the medical equipment provider's stock after selling 2,743,301 shares during the period. Legal & General Group Plc owned approximately 0.73% of Boston Scientific worth $959,190,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. TFC Financial Management Inc. lifted its position in shares of Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after buying an additional 210 shares in the last quarter. Dunhill Financial LLC raised its holdings in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 152 shares in the last quarter. Global Wealth Strategies & Associates boosted its position in shares of Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 250 shares during the last quarter. West Oak Capital LLC purchased a new position in shares of Boston Scientific in the fourth quarter valued at $29,000. Finally, Valley National Advisers Inc. increased its position in Boston Scientific by 262.4% in the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 286 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 12,000 shares of the business's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $105.48, for a total transaction of $1,265,760.00. Following the sale, the director now owns 24,398 shares in the company, valued at approximately $2,573,501.04. The trade was a 32.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 6,528 shares of the firm's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $104.97, for a total value of $685,244.16. Following the completion of the transaction, the executive vice president now owns 26,449 shares of the company's stock, valued at approximately $2,776,351.53. The trade was a 19.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 133,183 shares of company stock worth $13,948,476. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Up 1.1 %

Shares of NYSE BSX traded up $1.02 during mid-day trading on Friday, reaching $93.66. 8,303,541 shares of the company were exchanged, compared to its average volume of 6,351,456. The firm has a 50-day moving average of $100.54 and a 200 day moving average of $94.02. Boston Scientific Co. has a 1 year low of $66.80 and a 1 year high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a market cap of $138.53 billion, a price-to-earnings ratio of 74.93, a P/E/G ratio of 2.79 and a beta of 0.73.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. On average, research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on BSX. UBS Group increased their price objective on shares of Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Argus set a $130.00 price target on Boston Scientific in a research report on Tuesday, February 18th. Citigroup upped their price objective on Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. StockNews.com cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 8th. Finally, Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a report on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $109.04.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.